<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01267422</url>
  </required_header>
  <id_info>
    <org_study_id>RAVCT-2</org_study_id>
    <nct_id>NCT01267422</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)</brief_title>
  <acronym>rAAV2-ND4</acronym>
  <official_title>Safety and Efficacy Study of a Single Intravitreal Injection of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bin Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is meant to assess the safety and efficacy of rAAV2-ND4 treatment of Leber
      hereditary optic neuropathy with 11778 LHON mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Leber's Hereditary Optic Neuropathy (LHON) is a maternally inherited ocular disorder
      associated with a mutation in mtDNA . The common manifestation is visual loss which caused by
      the respiratory chain enzymes complex dysfunction resulting in increased oxidative stress
      enzymes production.

      Material and Method Seven patients with 11778 LHON mutation were randomly treated with a
      Single IVT Injection of recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4
      (complex I)（rAAV2-ND4)（0.05ml).The dose was 5 × 10^9 vg/0.05 mL for patients younger than 12
      years old, and 1 × 10^10 vg/0.05 mL for patients older than 12 years old. The visual acuity,
      visual evoked potential （VEP）,optical coherence tomography（ OCT）, computerized visual field,
      electroretinograms(ERG), retinal nerve fiber layer(RNFL)and Liver and kidney function in
      plasma were compared before and after treatment at 1,3,and 6, months interval.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Best Corrected Visual Acuity(BCVA)</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Results of CD3/CD4/CD8 Test</measure>
    <time_frame>up to 6 months</time_frame>
    <description>The mean percentage of CD3+/CD4+/CD8+ test before and after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure;</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing Antibody Assay</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The mean of Neutralizing antibody assay of 8 patients before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average RNFL Thickness Througth Optical Coherence Tomography(OCT) Test</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Average RNFL thickness of 8 patients througth Optical coherence tomography(OCT) test before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Computerized Visual Field(MD: Mean Deviation, the Value Close to 0 Regarded Normal)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>MD: mean deviation, the value Close to 0 regarded normal.VFI/MD：The bigger one was more close to the normal value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Computerized Visual Field(VFI: Visual Field Index ,the Value Close to 100% Regarded Normal)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>VFI: visual field index ,the value Close to 100% regarded normal. VFI/MD：The bigger one was more close to the normal value.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Leber Hereditary Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>rAAV2-ND4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rAAV2-ND4</intervention_name>
    <description>injection</description>
    <arm_group_label>rAAV2-ND4</arm_group_label>
    <other_name>rAAV2-ND4 gene therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. comply with Leber hereditary optic neuropathy diagnostic criteria.

          2. in patients with informed consent, voluntary participation.

          3. signed informed consent.

          4. 8 ≤ Age ≤ 60 years old, good health, the patient can tolerate local anesthesia
             surgery.

          5. to comply with doctor's instructions, can in the time of referral.

        Exclusion Criteria:

          1. Cardiopulmonary and renal function in severe weakness, cancer, a variety of bleeding
             disorders, acute sensing disease, high fever, high fever disease, women during
             pregnancy, heart disease, such as post-operative recovery period.

          2. Are participating in other clinical studies of patients.

          3. Patients with mental disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>bin Li, PhD,MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deputy Director of Ophthalmology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology ，Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Carelli V, Ross-Cisneros FN, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res. 2004 Jan;23(1):53-89. Review.</citation>
    <PMID>14766317</PMID>
  </reference>
  <reference>
    <citation>Mackey DA, Oostra RJ, Rosenberg T, Nikoskelainen E, Bronte-Stewart J, Poulton J, Harding AE, Govan G, Bolhuis PA, Norby S. Primary pathogenic mtDNA mutations in multigeneration pedigrees with Leber hereditary optic neuropathy. Am J Hum Genet. 1996 Aug;59(2):481-5.</citation>
    <PMID>8755941</PMID>
  </reference>
  <reference>
    <citation>Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, Elsas LJ 2nd, Nikoskelainen EK. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science. 1988 Dec 9;242(4884):1427-30.</citation>
    <PMID>3201231</PMID>
  </reference>
  <reference>
    <citation>Oguchi Y. [Past, present, and future in Leber's hereditary optic neuropathy]. Nippon Ganka Gakkai Zasshi. 2001 Dec;105(12):809-27. Review. Japanese.</citation>
    <PMID>11802455</PMID>
  </reference>
  <reference>
    <citation>Cui G, Ding H, Xu Y, Li B, Wang DW. Applications of the method of high resolution melting analysis for diagnosis of Leber's disease and the three primary mutation spectrum of LHON in the Han Chinese population. Gene. 2013 Jan 1;512(1):108-12. doi: 10.1016/j.gene.2012.09.110. Epub 2012 Oct 9.</citation>
    <PMID>23063736</PMID>
  </reference>
  <reference>
    <citation>Mashima Y, Kigasawa K, Wakakura M, Oguchi Y. Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy? J Neuroophthalmol. 2000 Sep;20(3):166-70.</citation>
    <PMID>11001192</PMID>
  </reference>
  <reference>
    <citation>Carelli V, Barboni P, Zacchini A, Mancini R, Monari L, Cevoli S, Liguori R, Sensi M, Lugaresi E, Montagna P. Leber's Hereditary Optic Neuropathy (LHON) with 14484/ND6 mutation in a North African patient. J Neurol Sci. 1998 Oct 8;160(2):183-8.</citation>
    <PMID>9849804</PMID>
  </reference>
  <reference>
    <citation>Barnils N, Mesa E, Muñoz S, Ferrer-Artola A, Arruga J. [Response to idebenone and multivitamin therapy in Leber's hereditary optic neuropathy]. Arch Soc Esp Oftalmol. 2007 Jun;82(6):377-80. Spanish.</citation>
    <PMID>17573650</PMID>
  </reference>
  <reference>
    <citation>Angebault C, Gueguen N, Desquiret-Dumas V, Chevrollier A, Guillet V, Verny C, Cassereau J, Ferre M, Milea D, Amati-Bonneau P, Bonneau D, Procaccio V, Reynier P, Loiseau D. Idebenone increases mitochondrial complex I activity in fibroblasts from LHON patients while producing contradictory effects on respiration. BMC Res Notes. 2011 Dec 22;4:557. doi: 10.1186/1756-0500-4-557.</citation>
    <PMID>22192149</PMID>
  </reference>
  <reference>
    <citation>Klopstock T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, Bailie M, Atawan A, Chattopadhyay S, Schubert M, Garip A, Kernt M, Petraki D, Rummey C, Leinonen M, Metz G, Griffiths PG, Meier T, Chinnery PF. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain. 2011 Sep;134(Pt 9):2677-86. doi: 10.1093/brain/awr170. Epub 2011 Jul 25.</citation>
    <PMID>21788663</PMID>
  </reference>
  <reference>
    <citation>Carelli V, La Morgia C, Valentino ML, Rizzo G, Carbonelli M, De Negri AM, Sadun F, Carta A, Guerriero S, Simonelli F, Sadun AA, Aggarwal D, Liguori R, Avoni P, Baruzzi A, Zeviani M, Montagna P, Barboni P. Idebenone treatment in Leber's hereditary optic neuropathy. Brain. 2011 Sep;134(Pt 9):e188. doi: 10.1093/brain/awr180. Epub 2011 Aug 2.</citation>
    <PMID>21810891</PMID>
  </reference>
  <reference>
    <citation>Sadun AA, Chicani CF, Ross-Cisneros FN, Barboni P, Thoolen M, Shrader WD, Kubis K, Carelli V, Miller G. Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy. Arch Neurol. 2012 Mar;69(3):331-8. doi: 10.1001/archneurol.2011.2972.</citation>
    <PMID>22410442</PMID>
  </reference>
  <reference>
    <citation>Newman NJ. Treatment of Leber hereditary optic neuropathy. Brain. 2011 Sep;134(Pt 9):2447-50. doi: 10.1093/brain/awr192. Epub 2011 Aug 22.</citation>
    <PMID>21859767</PMID>
  </reference>
  <reference>
    <citation>Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell'Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008 May 22;358(21):2240-8. doi: 10.1056/NEJMoa0802315. Epub 2008 Apr 27.</citation>
    <PMID>18441370</PMID>
  </reference>
  <reference>
    <citation>Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008 May 22;358(21):2231-9. doi: 10.1056/NEJMoa0802268. Epub 2008 Apr 27.</citation>
    <PMID>18441371</PMID>
  </reference>
  <reference>
    <citation>Bonnet C, Kaltimbacher V, Ellouze S, Augustin S, Bénit P, Forster V, Rustin P, Sahel JA, Corral-Debrinski M. Allotopic mRNA localization to the mitochondrial surface rescues respiratory chain defects in fibroblasts harboring mitochondrial DNA mutations affecting complex I or v subunits. Rejuvenation Res. 2007 Jun;10(2):127-44.</citation>
    <PMID>17518546</PMID>
  </reference>
  <reference>
    <citation>Ellouze S, Augustin S, Bouaita A, Bonnet C, Simonutti M, Forster V, Picaud S, Sahel JA, Corral-Debrinski M. Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction. Am J Hum Genet. 2008 Sep;83(3):373-87. doi: 10.1016/j.ajhg.2008.08.013. Epub 2008 Sep 4.</citation>
    <PMID>18771762</PMID>
  </reference>
  <reference>
    <citation>Koilkonda RD, Yu H, Chou TH, Feuer WJ, Ruggeri M, Porciatti V, Tse D, Hauswirth WW, Chiodo V, Boye SL, Lewin AS, Neuringer M, Renner L, Guy J. Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial. JAMA Ophthalmol. 2014 Apr 1;132(4):409-20. doi: 10.1001/jamaophthalmol.2013.7630.</citation>
    <PMID>24457989</PMID>
  </reference>
  <reference>
    <citation>Koilkonda R, Yu H, Talla V, Porciatti V, Feuer WJ, Hauswirth WW, Chiodo V, Erger KE, Boye SL, Lewin AS, Conlon TJ, Renner L, Neuringer M, Detrisac C, Guy J. LHON gene therapy vector prevents visual loss and optic neuropathy induced by G11778A mutant mitochondrial DNA: biodistribution and toxicology profile. Invest Ophthalmol Vis Sci. 2014 Oct 23;55(12):7739-53. doi: 10.1167/iovs.14-15388.</citation>
    <PMID>25342621</PMID>
  </reference>
  <reference>
    <citation>Shi H, Gao J, Pei H, Liu R, Hu WK, Wan X, Li T, Li B. Adeno-associated virus-mediated gene delivery of the human ND4 complex I subunit in rabbit eyes. Clin Exp Ophthalmol. 2012 Dec;40(9):888-94. doi: 10.1111/j.1442-9071.2012.02815.x. Epub 2012 Jul 2.</citation>
    <PMID>22612072</PMID>
  </reference>
  <reference>
    <citation>Mays LE, Vandenberghe LH, Xiao R, Bell P, Nam HJ, Agbandje-McKenna M, Wilson JM. Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins. J Immunol. 2009 May 15;182(10):6051-60. doi: 10.4049/jimmunol.0803965.</citation>
    <PMID>19414756</PMID>
  </reference>
  <reference>
    <citation>Hsu TK, Wang AG, Yen MY, Liu JH. Leber's hereditary optic neuropathy masquerading as optic neuritis with spontaneous visual recovery. Clin Exp Optom. 2014 Jan;97(1):84-6. doi: 10.1111/cxo.12100. Epub 2013 Aug 1.</citation>
    <PMID>23905692</PMID>
  </reference>
  <reference>
    <citation>Leo-Kottler B, Christ-Adler M. [Leber optic neuropathy in women and children]. Ophthalmologe. 1999 Nov;96(11):698-701. German.</citation>
    <PMID>10631830</PMID>
  </reference>
  <reference>
    <citation>Li H, Tuyishime S, Wu TL, Giles-Davis W, Zhou D, Xiao W, High KA, Ertl HC. Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice. Mol Ther. 2011 Mar;19(3):536-46. doi: 10.1038/mt.2010.267. Epub 2010 Dec 14.</citation>
    <PMID>21157435</PMID>
  </reference>
  <reference>
    <citation>Giordano C, Montopoli M, Perli E, Orlandi M, Fantin M, Ross-Cisneros FN, Caparrotta L, Martinuzzi A, Ragazzi E, Ghelli A, Sadun AA, d'Amati G, Carelli V. Oestrogens ameliorate mitochondrial dysfunction in Leber's hereditary optic neuropathy. Brain. 2011 Jan;134(Pt 1):220-34. doi: 10.1093/brain/awq276. Epub 2010 Oct 13.</citation>
    <PMID>20943885</PMID>
  </reference>
  <reference>
    <citation>Testa F, Maguire AM, Rossi S, Pierce EA, Melillo P, Marshall K, Banfi S, Surace EM, Sun J, Acerra C, Wright JF, Wellman J, High KA, Auricchio A, Bennett J, Simonelli F. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology. 2013 Jun;120(6):1283-91. doi: 10.1016/j.ophtha.2012.11.048. Epub 2013 Mar 6.</citation>
    <PMID>23474247</PMID>
  </reference>
  <reference>
    <citation>Yang S, He H, Zhu Y, Wan X, Zhou LF, Wang J, Wang WF, Liu L, Li B. Chemical and material communication between the optic nerves in rats. Clin Exp Ophthalmol. 2015 Nov;43(8):742-8. doi: 10.1111/ceo.12547. Epub 2015 Jun 25.</citation>
    <PMID>25950380</PMID>
  </reference>
  <reference>
    <citation>Ghelli A, Porcelli AM, Zanna C, Martinuzzi A, Carelli V, Rugolo M. Protection against oxidant-induced apoptosis by exogenous glutathione in Leber hereditary optic neuropathy cybrids. Invest Ophthalmol Vis Sci. 2008 Feb;49(2):671-6. doi: 10.1167/iovs.07-0880.</citation>
    <PMID>18235013</PMID>
  </reference>
  <reference>
    <citation>Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies. Prog Retin Eye Res. 2011 Mar;30(2):81-114. doi: 10.1016/j.preteyeres.2010.11.002. Epub 2010 Nov 26. Review.</citation>
    <PMID>21112411</PMID>
  </reference>
  <reference>
    <citation>Koilkonda RD, Guy J. Leber's Hereditary Optic Neuropathy-Gene Therapy: From Benchtop to Bedside. J Ophthalmol. 2011;2011:179412. doi: 10.1155/2011/179412. Epub 2010 Dec 26.</citation>
    <PMID>21253496</PMID>
  </reference>
  <results_reference>
    <citation>Wan X, Pei H, Zhao MJ, Yang S, Hu WK, He H, Ma SQ, Zhang G, Dong XY, Chen C, Wang DW, Li B. Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy. Sci Rep. 2016 Feb 19;6:21587. doi: 10.1038/srep21587.</citation>
    <PMID>26892229</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2010</study_first_submitted>
  <study_first_submitted_qc>December 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2010</study_first_posted>
  <results_first_submitted>May 21, 2015</results_first_submitted>
  <results_first_submitted_qc>March 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 2, 2016</results_first_posted>
  <last_update_submitted>January 7, 2018</last_update_submitted>
  <last_update_submitted_qc>January 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Bin Li</investigator_full_name>
    <investigator_title>Safety and Efficacy Study of rAAV2-ND4 Treatment of LHON</investigator_title>
  </responsible_party>
  <keyword>Leber's Hereditary Optic Neuropathy,11778 LHON mutation,</keyword>
  <keyword>rAAV2-ND4,triamcinolone acetonide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Atrophy, Hereditary, Leber</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients diagnosed with LHON (with a verified point mutation at the 11778 nucleotide site)</recruitment_details>
      <pre_assignment_details>All patients were administered rAAV2-ND4 by intravitreal injection to one eye and then followed for 36 months.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Participants Receiving Treatment in Left Eye</title>
          <description>5 participants receiving treatment in left eye</description>
        </group>
        <group group_id="P2">
          <title>Participants Receiving Treatment in Right Eye</title>
          <description>4 participants receiving treatment in right eye</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intravitreal rAAV2-ND4 Injection</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Safety and Efficacy Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Age,Gender,Ethnicity,Race,Region of Enrollment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" lower_limit="7.65" upper_limit="30.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Best Corrected Visual Acuity(BCVA)</title>
        <time_frame>Up to 3 years</time_frame>
        <population>The data are expressed as mean±standard error. Comparisons before and after treatment of the BCVA were analyzed using the paired t-test.A probability (P) value of less than 0.05 was considered statistically significant.Lower logMAR represents a better outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>BCVA of Un-treated Eyes</title>
            <description>BCVA of un-treated eyes in 9 patients</description>
          </group>
          <group group_id="O2">
            <title>BCVA of Treated Eyes</title>
            <description>BCVA of trearted eyes in 9 patients</description>
          </group>
        </group_list>
        <measure>
          <title>The Best Corrected Visual Acuity(BCVA)</title>
          <population>The data are expressed as mean±standard error. Comparisons before and after treatment of the BCVA were analyzed using the paired t-test.A probability (P) value of less than 0.05 was considered statistically significant.Lower logMAR represents a better outcome.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>logMAR</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>logMAR</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before treament</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.55"/>
                    <measurement group_id="O2" value="1.69" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 months after treament</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="0.58"/>
                    <measurement group_id="O2" value="1.58" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months after treament</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.58"/>
                    <measurement group_id="O2" value="1.38" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months after treament</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="0.68"/>
                    <measurement group_id="O2" value="1.23" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months after treament</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="0.62"/>
                    <measurement group_id="O2" value="1.27" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Results of CD3/CD4/CD8 Test</title>
        <description>The mean percentage of CD3+/CD4+/CD8+ test before and after treatment</description>
        <time_frame>up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>The Mean Percentage of CD3+/CD4+/CD8+ Before Treatment</title>
            <description>The mean percentage of CD3+ before treatment;The mean percentage of CD4+ before treatment;The mean percentage of CD8+ before treatment</description>
          </group>
          <group group_id="O2">
            <title>The Mean Percentage of CD3+/CD4+/CD8+ After Treatment</title>
            <description>The mean percentage of CD3+ after treatment;The mean percentage of CD4+ after treatment;The mean percentage of CD8+ after treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Results of CD3/CD4/CD8 Test</title>
          <description>The mean percentage of CD3+/CD4+/CD8+ test before and after treatment</description>
          <units>Percentage of total cells</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Values of CD3+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="50" upper_limit="84"/>
                    <measurement group_id="O2" value="53" lower_limit="50" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Values of CD4+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="20" upper_limit="51"/>
                    <measurement group_id="O2" value="20" lower_limit="20" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Values of CD8+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="12" upper_limit="45"/>
                    <measurement group_id="O2" value="13" lower_limit="12" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraocular Pressure;</title>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IOP Before Treatment</title>
            <description>Ophthalmologic examinations includes IOP of 9 paticipants before treatment</description>
          </group>
          <group group_id="O2">
            <title>IOP After Treatment</title>
            <description>Ophthalmologic examinations includes IOP of 9 participants after treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure;</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="10" upper_limit="21"/>
                    <measurement group_id="O2" value="16" lower_limit="10" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutralizing Antibody Assay</title>
        <description>The mean of Neutralizing antibody assay of 8 patients before and after treatment</description>
        <time_frame>up to 3 years</time_frame>
        <population>Neutralizing antibody assay of 8 patients except Patient 1 because he once accepted the other eye's treatment</population>
        <group_list>
          <group group_id="O1">
            <title>The Mean of Neutralizing Antibody Assay Before Treatment</title>
            <description>The mean of Neutralizing antibody assay before treatment of 8 patients</description>
          </group>
          <group group_id="O2">
            <title>The Mean of Neutralizing Antibody Assay After Treatment</title>
            <description>The mean of Neutralizing antibody assay after treatment of 8 patients</description>
          </group>
        </group_list>
        <measure>
          <title>Neutralizing Antibody Assay</title>
          <description>The mean of Neutralizing antibody assay of 8 patients before and after treatment</description>
          <population>Neutralizing antibody assay of 8 patients except Patient 1 because he once accepted the other eye's treatment</population>
          <units>titer</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9221" spread="0.142437"/>
                    <measurement group_id="O2" value="0.8723" spread="0.201054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average RNFL Thickness Througth Optical Coherence Tomography(OCT) Test</title>
        <description>Average RNFL thickness of 8 patients througth Optical coherence tomography(OCT) test before and after treatment</description>
        <time_frame>Up to 3 years</time_frame>
        <population>RNFL thickness of 8 patients except Patient 1 because he once accepted the other eye's treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Average RNFL Thickness Before Treatment</title>
            <description>Average RNFL thickness before treatment of injected eyes;Average RNFL thickness before treatment of uninjected eyes</description>
          </group>
          <group group_id="O2">
            <title>Average RNFL Thickness After Treatment</title>
            <description>Average RNFL thickness after treatment of injected eyes;Average RNFL thickness after treatment of uninjected eyes</description>
          </group>
        </group_list>
        <measure>
          <title>Average RNFL Thickness Througth Optical Coherence Tomography(OCT) Test</title>
          <description>Average RNFL thickness of 8 patients througth Optical coherence tomography(OCT) test before and after treatment</description>
          <population>RNFL thickness of 8 patients except Patient 1 because he once accepted the other eye's treatment</population>
          <units>Micrometer</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>injected eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3125" spread="7.87259"/>
                    <measurement group_id="O2" value="46.7813" spread="7.5397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>uninjected eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.1875" spread="13.402"/>
                    <measurement group_id="O2" value="47.9688" spread="9.7031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Computerized Visual Field(MD: Mean Deviation, the Value Close to 0 Regarded Normal)</title>
        <description>MD: mean deviation, the value Close to 0 regarded normal.VFI/MD：The bigger one was more close to the normal value.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Patient 2 refused the vision field test,there are MD outcome measure of 8 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Mean MD Before Treatment</title>
            <description>Mean MD before treatment of injected eyes;Mean MD before treatment of uninjected eyes</description>
          </group>
          <group group_id="O2">
            <title>Mean MD After Treatment</title>
            <description>Mean MD after treatment of injected eyes;Mean MD after treatment of uninjected eyes</description>
          </group>
        </group_list>
        <measure>
          <title>Computerized Visual Field(MD: Mean Deviation, the Value Close to 0 Regarded Normal)</title>
          <description>MD: mean deviation, the value Close to 0 regarded normal.VFI/MD：The bigger one was more close to the normal value.</description>
          <population>Patient 2 refused the vision field test,there are MD outcome measure of 8 patients.</population>
          <units>dB</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>injected eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.377" spread="5.16805"/>
                    <measurement group_id="O2" value="-23.813" spread="7.27537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>uninjected eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.701" spread="3.65595"/>
                    <measurement group_id="O2" value="-23.427" spread="8.15747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Computerized Visual Field(VFI: Visual Field Index ,the Value Close to 100% Regarded Normal)</title>
        <description>VFI: visual field index ,the value Close to 100% regarded normal. VFI/MD：The bigger one was more close to the normal value.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Patient 2 refused the vision field test,there are VFI outcome measure of 8 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Mean VFI Before Treatment</title>
            <description>Mean VFI before treatment of injected eyes;Mean VFI before treatment of uninjected eyes</description>
          </group>
          <group group_id="O2">
            <title>Mean VFI After Treatment</title>
            <description>Mean VFI after treatment of injected eyes;Mean VFI after treatment of uninjected eyes</description>
          </group>
        </group_list>
        <measure>
          <title>Computerized Visual Field(VFI: Visual Field Index ,the Value Close to 100% Regarded Normal)</title>
          <description>VFI: visual field index ,the value Close to 100% regarded normal. VFI/MD：The bigger one was more close to the normal value.</description>
          <population>Patient 2 refused the vision field test,there are VFI outcome measure of 8 patients.</population>
          <units>Percentage of normal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>injected eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="0.14513"/>
                    <measurement group_id="O2" value="28" spread="0.23305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>uninjected eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="0.28714"/>
                    <measurement group_id="O2" value="25" spread="0.24804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Short-term Affects</title>
          <description>Lens may be injured during intravitreal injection, and cataract is probably complicated. Retinal detachment or endophthalmitis may be complicated due to retina injury.IOP raised.Endophthalmitis after treament. Hyper-susceptibility or immune response during surgery or after surgery.</description>
        </group>
        <group group_id="E2">
          <title>Long-term Affects</title>
          <description>Lens may be injured after intravitreal injection, and cataract is probably complicated. Retinal detachment or endophthalmitis may be complicated due to retina injury.IOP raised.Blood and urine routine is affected.Liver and kidney function is affected.Immune response after surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Bin Li</name_or_title>
      <organization>Department of Ophthalmology, Tongji Hospital Tongji Medical College, Huazhong University of Science and Technology</organization>
      <phone>+86-13638673626</phone>
      <email>libin-12@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

